Sitemap
- Welcome to singular mAb experience
- Custom monoclonal antibody development
- Primary monoclonal antibodies
- Secondary monoclonal antibodies
- Immunoaffinity columns
- SynAbs recent news
- GPCR therapeutic monoclonal antibodies
- Ion channel therapeutic monoclonal antibodies
- Monoclonal antibody targeting virus envelope
- Epigenetics and Monoclonal histone modification antibodies
- Anti-Drug Antibody (ADA) generation
- Anti-small molecule hapten antibodies
- Recombinant antibodies
- Secondary monoclonal antibodies
- New primary monoclonal antibodies
- Microbiome, Cell & Gene Therapy
- Receptor tyrosine kinase therapeutic monoclonal antibodies
- Immunoglobulin SuperFamily (IgSF) therapeutic antibodies
- Contact SynAbs
Blog
- 06/09/2022 - TACA, promising oncology targets?
- 04/30/2022 - Therapeutic trends of G protein-coupled receptor drugs as Antibody Drug Conjugates candidates
- 04/05/2022 - CX3CR1, GPCR CX3C chemokine receptor 1 (CX3CR1): transmembrane receptor of therapeutic interest?
- 03/19/2022 - Immuno-Oncology Therapeutic Potential of Adenosine Receptors: Targeting the Purinergic Pathway
- 03/05/2022 - MARK & MARL SYnAbs mouse anti-rat light chain monoclonals
- 02/26/2022 - LO-MG SYnAbs rat-anti IgG mouse monoclonals
- 02/06/2022 - The therapeutic challenges of receptor tyrosine kinases
- 01/21/2022 - The enigmatic subclass antibody, SYngular products from SYnAbs
- 01/13/2022 - SYnAbs innovative monoclonal antibodies targeting hemoglobinopathia diseases
- 12/04/2021 - CD2, the missed opportunity for monoclonal antibody therapy?
- 10/30/2021 - The end of animal use for antibody generation in Europe. Really ?
- 10/02/2021 - Anti-CD25 therapeutic monoclonal antibody strategies
- 09/11/2021 - C3a and C5a anaphylatoxin receptors, therapeutic GPCR targets of the complement system
- 08/30/2021 - Therapeutic targets of the complement system
- 08/21/2021 - Monoclonal antibodies to human CD cell surface antigens
- 08/14/2021 - Orphan GPCR and their untapped therapeutic potential: the next wave of antibody drug targets?
- 06/30/2021 - CC chemokine receptors: latest news on Beta chemokine receptor therapeutics
- 06/10/2021 - Chemokine receptors: a promising GPCR family to target?
- 04/09/2021 - Functional antibodies: T-cell & B-cell depleting antibodies
- 03/19/2021 - SYnAbs and Belgian Volition ink strategic agreement on epigenetics
- 03/08/2021 - Viral Envelope Proteins, targets for Therapeutic Neutralizing Antibodies (NAbs)
- 02/20/2021 - Anti-drug antibody generation : How to effectively monitor your therapeutic drug
- 01/25/2021 - How do ion channels work?
- 01/11/2021 - A brief history of the discovery of ion channels
- 12/14/2020 - How does GPCR move? Learn the dynamics of the seven-(pass)-transmembrane domain receptors
- 11/28/2020 - Bald & Bearded : the DHT effect
- 11/14/2020 - Immunoaffinity chromatography : Principles and Tools of the market
- 11/06/2020 - Polyclonals & Oligoclonals: Alternatives to Monoclonals?
- 10/26/2020 - IL-1β monoclonal antibodies
- 10/24/2020 - Surrogate Antibodies & Therapeutic Monoclonals: Humans Mimicking Animals
- 10/17/2020 - Glycan & anti-glycan : the rise of glycobiology
- 10/06/2020 - TRAIL, the new Grail?
- 10/06/2020 - HEK293: when the virus meets the cell
- 10/05/2020 - History of GPCR and GPCR antibodies
- 10/01/2020 - Unique anti-valproic acid monoclonals
- 09/28/2020 - KIAA1199, Hybid or CEMIP? The same protein for a diversity of biological functions
- 09/23/2020 - Keeping Up with the SERPins
- 08/10/2020 - Microbiome: Zero to One
- 08/03/2020 - CHO cell line. A 60-year-old story.
- 07/17/2020 - Cancer & Bacteria, a long story rising from the ashes
- 07/01/2020 - IL1RAP, a new biomarker of interest for cancer targeting
- 06/26/2020 - An introduction to the Exosome world
- 06/23/2020 - Revealing the full potential of Adeno Associated Virus thanks to molecular biology
- 06/09/2020 - How much do you know about COVID-19 proteins?
- 05/25/2020 - Patients’ Immune Battle Against COVID-19
- 05/05/2020 - Latest News on COVID-19
- 04/03/2020 - Immune Response to Coronavirus infection
- 03/31/2020 - 11 Strategies To Treat Coronavirus You Should Know
- 03/17/2020 - Bispecific Antibody: The Janus God Of Therapeutics?
- 02/25/2020 - The Future Of Therapeutic Antibodies Development
- 02/19/2020 - More human than human is our motto
- 02/14/2020 - "Anta", "Block", "Neutra"...but Who Are They?
- 02/10/2020 - In Gut We Trust
- 02/04/2020 - Not One Monoclonal But Two mAbs can detect ANY PROTEIN!
- 01/30/2020 - The Dark Side Of CAR-T Therapy
- 01/16/2020 - In accordance with FDA, can a biotinylated mAb be replaced by a DNP marked mAb?
- 12/05/2019 - LO-HG4 Anti-human IgG4 monoclonal antibody
- 11/25/2019 - Hybridoma VS Display : The Fight Of The Century
- 11/14/2019 - Mycotoxins: the reign of terror
- 10/18/2019 - Are you sure you know everything about the Rat?
- 09/25/2019 - Three Letters You Should Be Aware Of
- 09/18/2019 - Most frequently asked questions on secondary antibodies
- 09/16/2019 - Your DNA isn't your destiny: news on epigenetics
- 07/02/2019 - mAbexperts commits to the future of immunotherapy: Complete VHH-CAR-T design
- 06/26/2019 - Best tips to select an outsourcing provider for custom antibody generation
- 04/27/2019 - The CAM family: a new target for monitoring or treating cancers?
- 04/20/2019 - SYnAbs and Univercells announce success on anti-biosimilar antibody assay
- 04/16/2019 - Why DNA immunization is still necessary?
- 04/12/2019 - Replacing in-vivo by an in-vitro test? Rabies mAb example
- 03/11/2019 - Neurogenic and SYnAbs deal for schizophrenia detection
- 01/28/2019 - Horiba & SYnAbs partnership : Production of monoclonal antibody directed against a steroid hormone and its binding study thanks to SPRi technology
- 08/28/2018 - SYnAbs is proud to announce ISO 9001:2015 certification!
- 12/14/2017 - SYnAbs/RD Biotech unique expertise in CAR-T cells
- 08/03/2016 - The small molecule detection challenge : the aflatoxin case study
SYnAbs S.A.
Rue Auguste Piccard, 48
I-Tech Incubator 2
B-6041 Gosselies
Belgium
+32 (0)71/374.880
BE 0637.716.206
